|1.||Tian, Jiahe: 1 article (11/2009)|
|2.||Zhang, Jinming: 1 article (11/2009)|
|3.||Wang, Xiaomin: 1 article (11/2009)|
|4.||Jia, Jun: 1 article (11/2009)|
|5.||Sun, Zuoli: 1 article (11/2009)|
|6.||Li, Bo: 1 article (11/2009)|
|7.||Liu, Limin: 1 article (11/2009)|
|8.||Wang, Yong: 1 article (11/2009)|
|9.||Zheng, Qi-Huang: 1 article (01/2009)|
|10.||Yoder, Karmen K: 1 article (01/2009)|
|1.||Parkinson Disease (Parkinson's Disease)
12/01/1999 - "There was a significant reduction in [(18)F]beta-CFT uptake in the posterior putamen (to 18% of the control mean, p<0.00001), anterior putamen (28%, p<0.00001), and caudate nucleus (51%, p<0.00001) in the total population of patients with Parkinson's disease. "
11/01/2009 - "Evaluation of nigrostriatal damage and its change over weeks in a rat model of Parkinson's disease: small animal positron emission tomography studies with [(11)C]beta-CFT."
02/01/1999 - "In this study, [18F]beta-CFT uptake was studied in nine patients with early Parkinson's disease (PD) without antiparkinsonian medication and in six age-matched controls. "
12/01/1999 - "[(18)F]beta-CFT is a sensitive marker of nigrostriatal dopaminergic dysfunction in Parkinson's disease and can be used in the diagnosis, assessment of disease severity, and follow up of patients."
12/01/1999 - "The reduction in [(18)F]beta-CFT uptake was more pronounced with more severe disability of the patients, the correlations between the total motor score of the unified Parkinson's disease rating scale (UPDRS) and [(18)F]beta-CFT uptake being significant in the posterior putamen (r=-0.62 p=0.0005), anterior putamen (r=-0.64, p=0.0003), and the caudate nucleus (r=-0.62, p=0.0006). "
09/01/1997 - "The effects of Zn2+, Mg2+, Hg2+, Li+, K+, and Na+ were assessed on the binding of [3H]mazindol and [3H]WIN 35,428 to the human (h) DAT expressed in C6 glioma cells under identical conditions for intact cell and membrane assays. "
08/01/1996 - "Translocation of [3H]dopamine and binding of [3H]WIN 35,428 were measured in intact C6 glioma cells expressing the cloned human dopamine transporter (hDAT) under identical conditions of assay buffer (phosphate-Krebs) and temperature (25 degrees C) with uptake at initial velocity and binding at equilibrium. "
08/01/1997 - "In the present study, we address this issue by examining the inhibition by mazindol of the binding of [3H]WIN 35,428 ([3H]2beta-carbomethyoxy-3beta-(4-fluorophenyl)-tropane), a phenyltropane analog of cocaine, and the inhibition by WIN 35,428 of [3H]mazindol binding to the cloned human dopamine transporter expressed in C6 glioma cells. "
11/08/1996 - "Binding sites for 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[3H]tropane ([3H]WIN 35,428) on the human dopamine transporter expressed in C6 glioma cells were alkylated with N-ethylmaleimide (NEM), and the protective potency of the blockers cocaine, N[1-(2-benzo[b]thiophenyl) cyclohexyl]piperidine (BTCP), and benztropine, and of the substrates dopamine, d-amphetamine, and norepinephrine was measured. "
01/03/2000 - "To explore the mechanisms underlying L-dopa response, we studied, by postmortem autoradiography, selective makers of dopamine presynaptic terminals, [3H]WIN 35428, and dopamine D2 receptors, [3H]nemonapride, in the putamen of four Parkinson's disease (PD) and one striatonigral degeneration (SND) neuropathologically confirmed brains as compared with six matched control brains. "
|5.||Cocaine-Related Disorders (Cocaine Addiction)
03/11/1999 - "As part of a program to develop site-specific medications for cocaine abuse, a series of 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane derivatives was synthesized and tested for inhibitory potency in [3H]WIN 35,428 binding and [3H]dopamine uptake assays using rat striatal tissue. "
|2.||Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
|3.||Cocaine (Cocaine HCl)
|5.||RTI 55 (Iometopane)
|6.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|7.||Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
|10.||Levodopa (L Dopa)